如何规范产后出血的药物治疗

摘要/Abstract

摘要：

产后出血（postpartum hemorrhage）是导致孕产妇死亡的首要原因。引起产后出血的原因分别为子宫收缩乏力、胎盘因素、软产道裂伤及凝血功能障碍。产后出血的病因治疗是最根本的治疗，是产后出血救治成功的关键。产后出血的药物治疗主要是针对子宫收缩乏力宫缩剂的治疗。缩宫素为一线用药，当单独手法按摩子宫和缩宫素不能达到止血目的时，可以考虑使用卡贝缩宫素、卡前列素氨丁三醇或卡前列酸栓。在没有注射用宫缩剂或注射用宫缩剂使用禁忌时可以考虑使用米索前列醇。当药物加强宫缩治疗无效时应注意不同药物的起效时间及持续时间。此外，一方面要重新核对有无合并其他原因所致产后出血；另一方面应及时采用必要的进一步治疗如宫腔填塞或子宫动脉栓塞等。

关键词: 产后出血, 药物治疗, 缩宫素

Abstract:

Abstract:Postpartum hemorrhage (PPH) is the leading cause of maternal mortality. The four Ts of PPH are Tone, Trauma, Tissue and Thrombin. Etiological treatment is the essential treatment. Uterotonic therapy is the most important medication of postpartum hemorrhage. The successful management of uterine atony will depend on the proper usage of the tocolytic agents, such as oxytocin, carboprost and misoprostol. Uterine packing and uterine artery embolism might be useful if the usage of tocolytic agents is not effective.

Key words: postpartum hemorrhage, medication, oxytocin

中图分类号:

R714.46+1

付晨薇，刘俊涛. 如何规范产后出血的药物治疗[J]. 中国实用妇科与产科杂志.

FU Chen-wei, LIU Jun-tao. Medication of postpartum hemorrhage[J]. Acta Metallurgica Sinica.

参考文献

[1］丰有吉，沈铿.妇产科学（供7年制及8年制临床医学生用）［M］.2版.北京：人民卫生出版社，2010：113-119.

[2］ WHO.WHO guidelines for the management of postpartum haemorrhage and retained placenta (issued 2009).

[3］ Su LL, Chong YS, Samuel M. Oxytocin agonists for preventing postpartum hemorrhage [J]. Cochrane Database Syst Rev, 2007,18(3):CD005457.

[4］ Blum J, Winikoff B, Raghavan S, et al. Treatment of post-hemorrhage with sublingual misoprostol versus oxytocin in women receiving prophylactic oxytocin:a double-blind, randomized, non-inferiority trial [J]. Lancet, 2010, 375:217-223.

[5］ Winikoff B, Dabash R, Durocher J, et al. Treatment of post-partum haemorrhage with sublingual misoprostol versus oxytocin in women not exposed to oxytocin during labour:a double-blind, randomized, non-inferiority trial [J]. Lancet, 2010,375:210-216.

[6］ Widmer M, Blum J, Hofmeyr GJ, et al. Misoprostol as an adjunct to standard uterotonics for treatment of post-partum haemorrhage:a multicentre, double-blind randomized trial [J]. Lancet, 2010,75:1808-1813.

[7］ Hofmeyr GJ, Walraven G, Gulmezoglu AM, et al. Misoprostol to treat postpartum haemorrhage:a systematic review [J]. BJOG, 2005, 112:547-553.

[8］ Tang J, Kapp N, Dragoman M,et al. WHO recommendations for misoprostol use for obstetric and gynecologic indications [J]. Int J Gynaecol Obstet, 2013, 121:186-189.

[9］ Lamont RF, Morgan DJ, Logue M, et al. A prospective randomized trial to compare the efficacy and safty of hemabate and syntometrine for the prevention of primary postpartum haemorrhage [J]. Prostalandins Other Lipid Mediat, 2001, 66(3):203-210.

[10］ Price G, Kaplan J,Skowronski G. Use of recombinant factor Ⅶa  to treat life-threatening non-surgical bleeding in a post-partum patient [J]. Br J Anaesth, 2004,93:298-300.

[1]	刘燕燕, 冯玲. 阴道分娩宫缩乏力性产后出血的早期识别及处理[J]. 中国实用妇科与产科杂志, 2022, 38(8): 773-776.
[2]	陈璐, 周微笑, 贺晶. 软产道裂伤致隐匿性产后出血的早期识别及处理[J]. 中国实用妇科与产科杂志, 2022, 38(8): 784-787.
[3]	张梓榆, 马晓欣. 子宫内膜息肉的药物治疗[J]. 中国实用妇科与产科杂志, 2022, 38(3): 266-269.
[4]	张国华, 沈雪艳, 崔文华. 继发性子宫收缩乏力出血病因查找、联合处置及弥散性血管内凝血防控[J]. 中国实用妇科与产科杂志, 2022, 38(2): 161-164.
[5]	彭超，周应芳. 药物治疗在子宫内膜异位症长期管理中的应用和选择[J]. 中国实用妇科与产科杂志, 2021, 37(3): 303-308.
[6]	张雪梅，漆洪波. 产后出血子宫切除对生活质量的影响[J]. 中国实用妇科与产科杂志, 2021, 37(2): 156-159.
[7]	赵扬玉，姜海. 妊娠及产后血栓性微血管病[J]. 中国实用妇科与产科杂志, 2021, 37(2): 189-192.
[8]	陈鹏, 刘兴会. 产后出血的预测和预警[J]. 中国实用妇科与产科杂志, 2021, 37(11): 1101-1105.
[9]	杨孜. 原发子宫收缩乏力产后出血预防行动的基点和预警[J]. 中国实用妇科与产科杂志, 2020, 36(8): 679-684.
[10]	刘兴会，何镭. 产后出血的预防和处理[J]. 中国实用妇科与产科杂志, 2020, 36(2): 123-126.
[11]	杨孜，段华. 卡前列甲酯临床应用专家共识（2020年版）[J]. 中国实用妇科与产科杂志, 2020, 36(11): 1091-1097.
[12]	中华医学会围产医学分会. 晚期产后出血诊治专家共识[J]. 中国实用妇科与产科杂志, 2019, 35(9): 1008-1013.
[13]	杨怡珂，漆洪波. 产后出血风险管理[J]. 中国实用妇科与产科杂志, 2019, 35(9): 978-982.
[14]	张慧英，薛凤霞. 子宫肌瘤的分型及临床决策[J]. 中国实用妇科与产科杂志, 2019, 35(8): 857-860.
[15]	林建华. 妊娠合并结构异常性心脏病并发产后出血MDT管理专家共识[J]. 中国实用妇科与产科杂志, 2019, 35(5): 528-535.